These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 30762246)

  • 61. A review of reported infectious events following rituximab therapy in pemphigus patients.
    Shahrigharahkoshan S; Dadkhahfar S; Mozafari N; Shahidi-Dadras M
    Dermatol Ther; 2022 Mar; 35(3):e15264. PubMed ID: 34907628
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Can rituximab be used in the treatment of pemphigus vulgaris during the COVID-19 pandemic?
    Uzuncakmak TK; Özkoca D; Askin O; Kutlubay Z
    Dermatol Ther; 2021 Jan; 34(1):e14647. PubMed ID: 33296557
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Rituximab in refractory autoimmune bullous diseases.
    Schmidt E; Hunzelmann N; Zillikens D; Bröcker EB; Goebeler M
    Clin Exp Dermatol; 2006 Jul; 31(4):503-8. PubMed ID: 16716150
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Assessment of the Effects of Rituximab Monotherapy on Different Subsets of Circulating T-Regulatory Cells and Clinical Disease Severity in Severe Pemphigus Vulgaris.
    Bhattacharjee R; De D; Handa S; Minz RW; Saikia B; Joshi N
    Dermatology; 2016; 232(5):572-577. PubMed ID: 27576321
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Therapy of pemphigus].
    van Beek N; Zillikens D; Schmidt E
    Hautarzt; 2019 Apr; 70(4):243-253. PubMed ID: 30887081
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Pemphigus foliaceus and acquired haemophilia: a rare but important association with life-threatening consequences.
    Wernham AG; Peng C; Bailiff B; Ilchyshyn A
    Clin Exp Dermatol; 2018 Oct; 43(7):825-828. PubMed ID: 29777540
    [No Abstract]   [Full Text] [Related]  

  • 67. Rituximab in refractory pemphigus vulgaris.
    Sorce M; Aricò M; Bongiorno MR
    Dermatol Ther; 2008 Jul; 21 Suppl 1():S6-9. PubMed ID: 18727815
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab).
    Marzano AV; Fanoni D; Venegoni L; Berti E; Caputo R
    Dermatology; 2007; 214(4):310-8. PubMed ID: 17460402
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Rituximab and low dose oral immune modulating treatment to maintain a sustained response in severe pemphigus patients.
    Keeley JM; Bevans SL; Jaleel T; Sami N
    J Dermatolog Treat; 2019 Jun; 30(4):340-345. PubMed ID: 30086663
    [No Abstract]   [Full Text] [Related]  

  • 70. Where does rituximab fit in the treatment of autoimmune mucocutaneous blistering skin disease?
    Nigam R; Levitt J
    J Drugs Dermatol; 2012 May; 11(5):622-5. PubMed ID: 22527431
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Rituximab exhibits a better safety profile when used as a first line of treatment for pemphigus vulgaris: A retrospective study.
    Aryanian Z; Balighi K; Daneshpazhooh M; Karamshahi E; Hatami P; Goodarzi A; Tajalli M; Vance TM
    Int Immunopharmacol; 2021 Jul; 96():107755. PubMed ID: 34162136
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Childhood pemphigus foliaceus. Report of a case.
    Sotiriou L; Herszenson S; Jordon RE
    Arch Dermatol; 1980 Jun; 116(6):679-80. PubMed ID: 6990872
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Low-dose rituximab is effective in pemphigus.
    Horváth B; Huizinga J; Pas HH; Mulder AB; Jonkman MF
    Br J Dermatol; 2012 Feb; 166(2):405-12. PubMed ID: 21967609
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Successful treatment with bendamustine and rituximab for paraneoplastic pemphigus.
    Kikuchi T; Mori T; Shimizu T; Koda Y; Abe R; Kurihara Y; Funakoshi T; Yamagami J; Sato H; Tsunoda K; Amagai M; Okamoto S
    Ann Hematol; 2017 Jul; 96(7):1221-1222. PubMed ID: 28447163
    [No Abstract]   [Full Text] [Related]  

  • 75. Pediatric autoimmune blistering disorders - a five-year demographic profile and therapy experience.
    Mahajan R; Handa S; Kumar S; Chatterji D; Saikia UN; De D
    Int J Dermatol; 2022 Dec; 61(12):1511-1518. PubMed ID: 35894223
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Pemphigus foliaceus presenting as eruptive seborrheic keratosis and responding to oral gold treatment.
    Bagheri MM; Alagheband M; Memar OM; Eiler DB
    J Drugs Dermatol; 2002 Dec; 1(3):333-4. PubMed ID: 12851996
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Pilot study of 19 patients with severe pemphigus: prophylactic treatment with rituximab does not appear to be beneficial.
    Gregoriou S; Giatrakou S; Theodoropoulos K; Katoulis A; Loumou P; Toumbis-Ioannou E; Papadavid E; Avgerinou G; Stavrianeas N; Rigopoulos D
    Dermatology; 2014; 228(2):158-65. PubMed ID: 24557145
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Therapy with rituximab for autoimmune pemphigus: results from a single-center observational study on 42 cases with long-term follow-up.
    Cianchini G; Lupi F; Masini C; Corona R; Puddu P; De Pità O
    J Am Acad Dermatol; 2012 Oct; 67(4):617-22. PubMed ID: 22243765
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Rituximab as a maintenance treatment in patients with pemphigus vulgaris: When is the right time for discontinuation?
    Aryanian Z; Balighi K; Emadi SN; Hatami P
    J Cosmet Dermatol; 2024 Feb; 23(2):406-408. PubMed ID: 37916650
    [No Abstract]   [Full Text] [Related]  

  • 80. Rituximab therapy in pemphigus foliaceus: report of 12 cases and review of recent literature.
    de Sena Nogueira Maehara L; Huizinga J; Jonkman MF
    Br J Dermatol; 2015; 172(5):1420-3. PubMed ID: 25496559
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.